AcuraStem, a Pasadena, CA-based patient-based biotechnology company advancing treatments for neurodegenerative diseases, received a $7M Grant.
The National Institutes of Health (NIH) and Department of Defense (DOD) provided the grant.
This latest achievement—building upon the recent licensing agreement with Takeda worth $580M to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202—enables the company to advance multiple programs towards clinical trials.
Led by Sam Alworth, MS, MBA, and CEO, AcuraStem is a patient-based biotechnology company working on treatments for neurodegenerative diseases including sporadic ALS and FTD. Its disease modeling platform, iNeuroRx®, enables the discovery of innovative, effective, and broadly acting treatments. The team’s expertise in ASO technology provides for the advancement of treatments to the clinic. AcuraStem’s research is funded in part by support from the Alzheimer’s Drug Discovery Foundation, Harrington Discovery Institute, Alzheimer’s Association, Rainwater Charitable Foundation, Muscular Dystrophy Association, Department of Defense and the National Institute of Neurological Disorders and Stroke.
